| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
COX-1 1.9 μM (IC50) COX-2 9.9 μM (IC50) VEGFR2 0.92 μM (IC50)
|
|---|---|
| ln Vitro |
(±)-Aiphanol (7.5-30 μM; 6 h) inhibits VEGF-induced neovascularization in HUVECs in a dose-dependent manner. It significantly reduces the levels of PGE2 and VEGF in HUVECs, an effect that disappears after COX2 silencing. It is more potent than Celecoxib (HY-14398) in inhibiting VEGF-induced tubular structure formation in HUVECs[2]. (±)-Aiphanol (7.5-30 μM; 6h) significantly inhibits microvascular growth in CAM, with an effect comparable to that of Bevacizumab (HY-P9906)[2]. (±)-Aiphanol inhibits the activity of VEGFR3/FLT4, VEGFR2/KDR, and VEGFR1/FLT1, and has moderate or weak inhibitory effects on certain kinases in the PI3K-AKT and MAPK pathways[2]. (±)-Aiphanol (30 μM; 24 h) inhibited the proliferation of HUVECs and induced cell apoptosis[2].
|
| ln Vivo |
(±)-Aiphanol (30 mg/kg; po; single dose) significantly inhibits tumor growth and significantly reduces tumor weight in the MC38 syngeneic mouse model [2].
|
| Cell Assay |
Apoptosis Analysis[2]
Cell Types: HUVECs Concentration: 30 μM Incubation Duration: 24 h Experimental Results: Did not cause significant changes in cell cycle distribution but significantly increased apoptosis. Elevated the expression of P53 and BAX proteins. |
| Animal Protocol |
Animal/Disease Models:MC38 syngeneic mouse model[2]
Doses: 30 mg/kg Route of Administration: p.o.; single dose Experimental Results: Increased apoptosis in tumor tissues and reduced the phosphorylation levels of VEGFR2, AKT, and ERK. Significantly decreased the levels of vascular markers CD31 and factor VIII. Lowered the levels of PGE2 in plasma and VEGF in tumor tissues. Did not cause changes in body weight or the morphology of major organs. |
| References | |
| Additional Infomation |
Aiphanol is a lignan that is (2R)-2,3-dihydro-1,4-benzodioxin-2-ylmethanol which is substituted by a 2-(3,5-dihydroxyphenyl)ethenyl group at position 6 and a 4-hydroxy-3,5-dimethoxyphenyl group at position 3. It is a stilbenolignan isolated from the seeds of Aiphanes aculeata and exhibits potent inhibitory efficacy against cyclooxygenase-1 and -2 (COX-1 and COX-2). It has a role as an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor. It is a stilbenoid, a lignan, an aromatic ether and a benzodioxine.
Aiphanol has been reported in Aiphanes horrida with data available. |
| Molecular Formula |
C25H24O8
|
|---|---|
| Molecular Weight |
452.45
|
| Exact Mass |
452.147
|
| CAS # |
578020-29-8
|
| PubChem CID |
10366595
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.7
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
33
|
| Complexity |
620
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O1C2C=C(/C=C/C3C=C(C=C(C=3)O)O)C=CC=2O[C@H](CO)[C@H]1C1C=C(C(=C(C=1)OC)O)OC
|
| InChi Key |
KDMFHGGHQLUIRH-OOODPRFPSA-N
|
| InChi Code |
InChI=1S/C25H24O8/c1-30-21-10-16(11-22(31-2)24(21)29)25-23(13-26)32-19-6-5-14(9-20(19)33-25)3-4-15-7-17(27)12-18(28)8-15/h3-12,23,25-29H,13H2,1-2H3/b4-3+/t23-,25-/m1/s1
|
| Chemical Name |
5-[(E)-2-[(2R,3R)-3-(4-hydroxy-3,5-dimethoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]ethenyl]benzene-1,3-diol
|
| Synonyms |
Aiphanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2102 mL | 11.0509 mL | 22.1019 mL | |
| 5 mM | 0.4420 mL | 2.2102 mL | 4.4204 mL | |
| 10 mM | 0.2210 mL | 1.1051 mL | 2.2102 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
